EUCTR2014-004852-77-NL进行中（未招募）1 期
AN OPEN-LABEL, PHASE Ia/Ib/IIa STUDY OF GDC-0810 SINGLE AGENT ORIN COMBINATION WITH PALBOCICLIB AND/OR AN LHRH AGONIST INWOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTORPOSITIVE BREAST CANCER
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •General inclusion criteria:
- •-Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally recurrent disease not amenable to resection or radiation therapy with curative intent, or metastatic disease, both progressing after at least 6 months of hormonal therapy for ER+ breast cancer
- •- ER-positive, HER2-negative
- •- At least 2 months must have elapsed from the use of tamoxifen
- •- At least 6 months must have elapsed from the use of fulvestrant
- •- At least 2 weeks must have elapsed from the use of any other anticancer hormonal therapy
- •- At least 3 weeks must have elapsed from the use of any chemotherapy
- •- Females, 18 years of age or older
- •- Postmenopausal status
- •- Eastern Cooperative Oncology Group (ECOG) performance status
- •- Adequate organ function
- •Phase II portion - all general above inclusion criteria, plus:
- •- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •- At least 6 months must have elapsed from the use of fulvestrant not applicable
- •- Cohort A only: Confirmed ESR1 mutation and presence of measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or evaluable bone disease
- •- Cohort A1 only: no prior fulvestrant allowed; at least 2 months must have elapsed from the use of tamoxifen
- •- Cohort A2 only: prior fulvestrant allowed
- •- Cohort B only: disease progression following no more than 1 prior treatment with an aromatase inhibitor in the advanced/metastatic setting
- •- Cohort B1 only: no prior fulvestrant allowed
- •- Cohort B2 only: prior fulvestrant allowed
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 62
排除标准
- •General exclusion criteria:
- •- Untreated or symptomatic CNS metastases
- •- Patients with a history of endometrial polyps, endometrial cancer,
- •atypical endometrial hyperplasia, or other significant endometrial
- •disorders should be excluded unless they have undergone total
- •hysterectomy and there is no evidence of active disease.
- •- More than 2 prior chemotherapy in the advanced/metastatic setting (prior adjuvant chemotherapy is allowed so long as it occurred >/= 12 months prior to enrollment)
- •- Current treatment with any systemic anticancer therapies for advanced disease or any systemic experimental treatment on another clinical trial
- •- Any significant cardiac dysfunction within 12 months prior to enrollment
- •- Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
- •- Known human immunodeficiency virus infection
- •- Major surgery within 4 weeks prior to enrollment
- •- Radiation therapy within 2 weeks prior to enrollment
- •Phase IIa portion - all general exclusion criteria, plus:
- •- Cohort A1, A2, and Cohort B2 only: > 1 prior chemotherapy in the advanced/metastatic setting
- •- Cohort B1 only: prior chemotherapy in the advanced/metastatic setting
研究者
相似试验
已完成
2 期
AN OPEN-LABEL, PHASE Ia/Ib/IIa STUDY OF GDC 0810 SINGLE AGENT OR IN COMBINATION WITH PALBOCICLIB AND/OR AN LHRH AGONIST IN WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCEREstrogen receptor positive breast cancer10006291NL-OMON45124Genentech, Inc4
进行中（未招募）
1 期
A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerEUCTR2014-004852-77-ESGenentech, Inc141
进行中（未招募）
1 期
A Study of GDC-0810 versus Fulvestrant in Postmenopausal Women with Advanced or Metastatic ER+/HER2- Breast Cancer Resistant To Aromatase Inhibitor TherapyAdvanced or Metastatic ER+/HER2- Breast CancerMedDRA version: 18.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2015-000106-19-ESGenentech, Inc152
进行中（未招募）
1 期
A Study of GDC-0810 versus Fulvestrant in Postmenopausal Women with Advanced or Metastatic ER+/HER2- Breast Cancer Resistant To Aromatase Inhibitor TherapyEUCTR2015-000106-19-DEGenentech, Inc152
进行中（未招募）
1 期
An evaluation of the investigational drug GDC-0980 in patients with metastatic kidney cancer who have already received up to three therapies, with the approved drug everolimus as a comparisoMETASTATIC RENAL CELL CARCINOMAMedDRA version: 14.1 Level: LLT Classification code 10038415 Term: Renal cell carcinoma stage unspecified System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: LLT Classification code 10038407 Term: Renal cell cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: LLT Classification code 10038409 Term: Renal cell carcinoma NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000493-56-GBGENENTECH, Inc.85